RZLT
Rezolute, Inc.
-0.01 (-0.25%)3.97USD893K成交股數382M市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-09-17下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 29K · 0.00 |
| 近 180 天 淨額 | 29K |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-02 | 09-03 | Karnawat Sunil Ratilal | Chief Commercial Officer | F 繳稅扣股 | 2.3K | 4.50 | 10K | 69.3K | SEC |
| 2026-07-02 | 07-07 | Evans Daron | CFO | F 繳稅扣股 | 3.1K | 4.99 | 15K | 411K | SEC |
| 2026-07-02 | 07-07 | ROBERTS BRIAN KENNETH | Chief Medical Officer | F 繳稅扣股 | 3.1K | 4.99 | 15K | 294K | SEC |
| 2026-07-02 | 07-07 | Elam Nevan C | CEO | F 繳稅扣股 | 8.0K | 4.99 | 40K | 605K | SEC |
| 2026-03-30 | 03-31 | Evans Daron | CFO | P 公開市場買進 | 10.0K | 2.85 | 29K | 414K | SEC |
| 2026-03-02 | 03-04 | Elam Nevan C | CEO | F 繳稅扣股 | 27.6K | 2.99 | 83K | 614K | SEC |
| 2026-03-02 | 03-04 | Evans Daron | CFO | F 繳稅扣股 | 11.4K | 2.99 | 34K | 404K | SEC |
| 2026-03-02 | 03-04 | ROBERTS BRIAN KENNETH | Chief Medical Officer | F 繳稅扣股 | 11.4K | 2.99 | 34K | 297K | SEC |
| 2025-12-16 | 12-17 | Hogenhuis Wladimir | Director | P 公開市場買進 | 5.7K | 1.69 | 10K | 120K | SEC |
| 2025-12-16 | 12-17 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 28.0K | 1.70 | 48K | 308K | SEC |
| 2025-12-15 | 12-15 | Evans Daron | CFO | P 公開市場買進 | 2.5K | 1.79 | 4K | 7.0K | SEC |
| 2025-12-15 | 12-15 | Evans Daron | CFO | P 公開市場買進 | 40.0K | 1.77 | 71K | 416K | SEC |
| 2025-12-15 | 12-15 | Karnawat Sunil Ratilal | Chief Commercial Officer | P 公開市場買進 | 100 | 1.60 | 160.00 | 71.5K | SEC |
| 2025-12-15 | 12-15 | Evans Daron | CFO | P 公開市場買進 | 2.5K | 1.79 | 4K | 7.0K | SEC |
| 2025-12-15 | 12-15 | Elam Nevan C | CEO | P 公開市場買進 | 32.0K | 1.59 | 51K | 641K | SEC |
| 2025-12-15 | 12-15 | Karnawat Sunil Ratilal | Chief Commercial Officer | P 公開市場買進 | 12.0K | 1.62 | 19K | 71.4K | SEC |
| 2025-12-09 | 12-10 | Evans Daron | CFO | P 公開市場買進 | 10.5K | 5.04 | 53K | 132K | SEC |
| 2025-11-19 | 11-21 | Labrucherie Gil M | Director | A 獲配股票 | 21.0K | – | – | 55.5K | SEC |
| 2025-11-19 | 11-21 | Karnawat Sunil Ratilal | Chief Commercial Officer | A 獲配股票 | 32.0K | – | – | 59.4K | SEC |
| 2025-11-19 | 11-21 | ROBERTS BRIAN KENNETH | Chief Medical Officer | A 獲配股票 | 123K | – | – | 280K | SEC |
| 2025-11-19 | 11-21 | Elam Nevan C | CEO | A 獲配股票 | 317K | – | – | 609K | SEC |
| 2025-11-19 | 11-21 | Evans Daron | CFO | A 獲配股票 | 107K | – | – | 376K | SEC |
| 2025-11-19 | 11-21 | KREHER NERISSA | Director | A 獲配股票 | 21.0K | – | – | 58.6K | SEC |
| 2025-11-19 | 11-21 | Harris Erik | Director | A 獲配股票 | 21.0K | – | – | 21.0K | SEC |
| 2025-11-19 | 11-21 | Hogenhuis Wladimir | Director | A 獲配股票 | 21.0K | – | – | 114K | SEC |
| 2025-11-19 | 11-21 | FAUCHET PHILIPPE | Director | A 獲配股票 | 21.0K | – | – | 55.5K | SEC |
| 2025-11-19 | 11-21 | Kim Young-Jin | Director | A 獲配股票 | 21.0K | – | – | 171K | SEC |
| 2025-08-18 | 08-27 | Karnawat Sunil Ratilal | Chief Commercial Officer | A 獲配股票 | 25.0K | – | – | 27.4K | SEC |
| 2025-06-25 | 06-26 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 2.5K | 4.38 | 11K | 15.5K | SEC |
| 2025-06-24 | 06-24 | Evans Daron | CFO | P 公開市場買進 | 5.0K | 4.05 | 20K | 269K | SEC |
| 2025-06-13 | 06-23 | Kim Young-Jin | Director | P 公開市場買進 | 1.2M | 3.25 | 4.0M | 8.4M | SEC |
| 2025-06-13 | 06-23 | KREHER NERISSA | Director | P 公開市場買進 | 3.1K | 3.25 | 10K | 37.6K | SEC |
| 2025-06-10 | 06-13 | Hogenhuis Wladimir | Director | A 獲配股票 | 9.0K | – | – | 93.0K | SEC |
| 2025-06-10 | 06-13 | Labrucherie Gil M | Director | A 獲配股票 | 9.0K | – | – | 34.5K | SEC |
| 2025-06-10 | 06-13 | KREHER NERISSA | Director | A 獲配股票 | 9.0K | – | – | 34.5K | SEC |
| 2025-06-10 | 06-12 | ROBERTS BRIAN KENNETH | Chief Medical Officer | A 獲配股票 | 26.0K | – | – | 157K | SEC |
| 2025-06-10 | 06-12 | Elam Nevan C | CEO | A 獲配股票 | 68.0K | – | – | 292K | SEC |
| 2025-06-10 | 06-12 | Kim Young-Jin | Director | A 獲配股票 | 9.0K | – | – | 150K | SEC |
| 2025-06-10 | 06-12 | Evans Daron | CFO | A 獲配股票 | 26.0K | – | – | 264K | SEC |
| 2025-06-10 | 06-12 | FAUCHET PHILIPPE | Director | A 獲配股票 | 9.0K | – | – | 34.5K | SEC |
| 2025-03-31 | 04-01 | Hogenhuis Wladimir | Director | P 公開市場買進 | 6.8K | 2.92 | 20K | 84.0K | SEC |
| 2025-03-27 | 03-31 | Elam Nevan C | CEO | P 公開市場買進 | 12.3K | 2.85 | 35K | 224K | SEC |
| 2025-03-26 | 03-28 | Evans Daron | CFO | P 公開市場買進 | 10.0K | 2.88 | 29K | 23.0K | SEC |
| 2025-03-26 | 03-28 | Evans Daron | CFO | P 公開市場買進 | 10.0K | 2.89 | 29K | 238K | SEC |
| 2025-02-18 | 02-20 | Hogenhuis Wladimir | Director | P 公開市場買進 | 10.0K | 4.70 | 47K | 77.3K | SEC |
| 2025-02-16 | 02-20 | Hogenhuis Wladimir | Director | A 獲配股票 | 25.5K | – | – | 67.3K | SEC |
| 2025-02-16 | 02-20 | Labrucherie Gil M | Director | A 獲配股票 | 25.5K | – | – | 25.5K | SEC |
| 2025-02-16 | 02-19 | Elam Nevan C | CEO | A 獲配股票 | 204K | – | – | 212K | SEC |
| 2025-02-16 | 02-19 | Evans Daron | CFO | A 獲配股票 | 77.0K | – | – | 228K | SEC |
| 2025-02-16 | 02-19 | FAUCHET PHILIPPE | Director | A 獲配股票 | 25.5K | – | – | 25.5K | SEC |
| 2025-02-16 | 02-19 | Kim Young-Jin | Director | A 獲配股票 | 25.5K | – | – | 141K | SEC |
| 2025-02-16 | 02-19 | ROBERTS BRIAN KENNETH | Chief Medical Officer | A 獲配股票 | 77.0K | – | – | 131K | SEC |
| 2025-02-16 | 02-19 | KREHER NERISSA | Director | A 獲配股票 | 25.5K | – | – | 25.5K | SEC |
| 2024-12-18 | 12-18 | Evans Daron | CFO | P 公開市場買進 | 10.0K | 4.29 | 43K | 151K | SEC |
| 2024-12-12 | 12-12 | Evans Daron | CFO | P 公開市場買進 | 9.0K | 4.60 | 41K | 141K | SEC |
| 2024-09-24 | 09-24 | Hogenhuis Wladimir | Director | P 公開市場買進 | 4.3K | 4.70 | 20K | 41.8K | SEC |
| 2024-06-25 | 02-19 | Kim Young-Jin | Director | P 公開市場買進 | 1.3M | 4.00 | 5.0M | 7.2M | SEC |
| 2024-06-25 | 06-27 | Hogenhuis Wladimir | Director | P 公開市場買進 | 4.8K | 4.15 | 20K | 37.5K | SEC |
| 2024-06-14 | 06-14 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 300 | 3.97 | 1K | 1.4K | SEC |
| 2024-06-14 | 06-14 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 3.0K | 3.91 | 12K | 13.0K | SEC |
| 2024-06-14 | 06-14 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 300 | 3.96 | 1K | 54.4K | SEC |
| 2024-06-14 | 06-14 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 4.0K | 3.91 | 16K | 54.1K | SEC |
| 2024-06-14 | 06-14 | Evans Daron | CFO | P 公開市場買進 | 40.0K | 4.04 | 162K | 40.0K | SEC |
| 2024-05-29 | 05-31 | Evans Daron | CFO | P 公開市場買進 | 451 | 3.50 | 2K | 121K | SEC |
| 2024-05-24 | 05-28 | Evans Daron | CFO | P 公開市場買進 | 2.9K | 3.23 | 10K | 13.0K | SEC |
| 2024-05-23 | 05-28 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 6.0K | 2.68 | 16K | 50.1K | SEC |
| 2024-05-23 | 05-28 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 1.5K | 2.72 | 4K | 44.1K | SEC |
| 2024-05-23 | 05-28 | Evans Daron | CFO | P 公開市場買進 | 58 | 2.85 | 165.30 | 10.1K | SEC |
| 2024-03-28 | 03-29 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 500 | 2.55 | 1K | 1.1K | SEC |
| 2024-03-15 | 03-19 | Evans Daron | CFO | P 公開市場買進 | 20.0K | 1.69 | 34K | 20.0K | SEC |
| 2024-03-14 | 03-18 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 10.0K | 1.88 | 19K | 10.0K | SEC |
| 2024-03-08 | 03-08 | Evans Daron | CFO | P 公開市場買進 | 50.0K | 1.93 | 97K | 121K | SEC |
| 2024-03-07 | 03-18 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 500 | 1.85 | 925.00 | 576 | SEC |
| 2024-03-07 | 03-14 | Kim Young-Jin | Director | P 公開市場買進 | 36.5K | 1.91 | 70K | 115K | SEC |
| 2024-03-07 | 03-11 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 500 | 1.85 | 925.00 | 500 | SEC |
| 2024-02-26 | 02-28 | Elam Nevan C | CEO | P 公開市場買進 | 5.0K | 1.68 | 8K | 7.8K | SEC |
| 2024-02-26 | 02-27 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 2.0K | 1.70 | 3K | 42.6K | SEC |
| 2024-02-23 | 02-27 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 6.0K | 1.69 | 10K | 40.6K | SEC |
| 2024-02-16 | 02-21 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P 公開市場買進 | 7.0K | 1.31 | 9K | 34.6K | SEC |
| 2024-02-16 | 02-20 | Evans Daron | CFO | P 公開市場買進 | 41.9K | 1.30 | 54K | 70.9K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| FEDERATED HERMES, INC. | 13.0M | 67.6M | 新進 | 新進 |
| RA CAPITAL MANAGEMENT, L.P. | 9.4M | 49.1M | 新進 | 新進 |
| BlackRock, Inc. | 7.7M | 40.1M | 新進 | 新進 |
| Opaleye Management Inc. | 6.3M | 32.8M | 新進 | 新進 |
| Balyasny Asset Management L.P. | 4.7M | 24.2M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8M | 19.9M | 新進 | 新進 |
| Siren, L.L.C. | 3.3M | 17.3M | 新進 | 新進 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2.6M | 13.3M | 新進 | 新進 |
| JENNISON ASSOCIATES LLC | 2.5M | 12.8M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2M | 11.3M | 新進 | 新進 |
| STATE STREET CORP | 1.9M | 9.6M | 新進 | 新進 |
| 德劭 D. E. Shaw & Co., Inc. | 1.8M | 9.6M | 新進 | 新進 |
| MORGAN STANLEY | 1.6M | 8.4M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.4M | 7.2M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 1.3M | 6.8M | 新進 | 新進 |
| Nuveen, LLC | 1.3M | 6.7M | 新進 | 新進 |
| KENNEDY CAPITAL MANAGEMENT LLC | 1.2M | 6.4M | 新進 | 新進 |
| Blackstone Inc. | 1.1M | 5.6M | 新進 | 新進 |
| AQR CAPITAL MANAGEMENT LLC | 1.0M | 5.2M | 新進 | 新進 |
| Affinity Asset Advisors, LLC | 1.0M | 5.2M | 新進 | 新進 |
| GREAT POINT PARTNERS LLC | 952K | 4.9M | 新進 | 新進 |
| Ikarian Capital, LLC | 935K | 4.9M | 新進 | 新進 |
| DIMENSIONAL FUND ADVISORS LP | 891K | 4.6M | 新進 | 新進 |
| 22NW, LP | 821K | 4.3M | 新進 | 新進 |
| Velan Capital Investment Management LP | 750K | 3.9M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 144 +18 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 144 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 86.6M · 90.0% |
| 合計季末市值 | 449M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 17.0M |
|---|---|
| 與上期比 | +2.9% |
| 佔流通股數 | 17.65% |
| 日均成交量 | 1.5M |
| 回補天數 | 11.0 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 17.0M | +2.9% | 17.65% | 1.5M | 11.0 |
| 2026-08-14 | 16.5M | -2.1% | 17.16% | 1.2M | 13.3 |
| 2026-07-31 | 16.9M | +3.5% | 17.53% | 1.1M | 15.0 |
| 2026-07-15 | 16.3M | -0.6% | 16.94% | 1.9M | 8.8 |
| 2026-06-30 | 16.4M | +18.8% | 17.04% | 2.8M | 5.9 |
| 2026-06-15 | 13.8M | +0.7% | 14.35% | 2.6M | 5.4 |
| 2026-05-29 | 13.7M | -5.9% | 14.24% | 1.2M | 11.9 |
| 2026-05-15 | 14.6M | +6.3% | 15.15% | 1.2M | 12.0 |
| 2026-04-30 | 13.7M | +6.7% | 14.25% | 1.5M | 9.4 |
| 2026-04-15 | 12.9M | -3.6% | 13.37% | 1.5M | 8.6 |
| 2026-03-31 | 13.4M | -21.2% | 13.87% | 4.6M | 2.9 |
| 2026-03-13 | 16.9M | +0.5% | 17.59% | 1.7M | 10.0 |
| 2026-02-27 | 16.9M | -6.0% | 17.51% | 1.8M | 9.6 |
| 2026-02-13 | 17.9M | -5.5% | 18.63% | 3.2M | 5.6 |
| 2026-01-30 | 19.0M | +0.5% | 19.71% | 3.1M | 6.1 |
| 2026-01-15 | 18.9M | +46.4% | 19.62% | 5.5M | 3.4 |
| 2025-12-31 | 12.9M | +5.6% | 13.40% | 10.0M | 1.3 |
| 2025-12-15 | 12.2M | +16.6% | 12.69% | 17.3M | 1.0 |
| 2025-11-28 | 10.5M | -2.4% | 10.89% | 1.4M | 7.7 |
| 2025-11-14 | 10.7M | +0.9% | 11.15% | 1.6M | 6.9 |
| 2025-10-31 | 10.6M | +11.7% | 11.05% | 1.5M | 7.0 |
| 2025-10-15 | 9.5M | +0.1% | 9.89% | 1.4M | 6.9 |
| 2025-09-30 | 9.5M | +23.9% | 9.88% | 1.9M | 5.0 |
| 2025-09-15 | 7.7M | +3.5% | 7.97% | 836K | 9.2 |
| 2025-08-29 | 7.4M | +0.0% | 7.70% | 893K | 8.3 |
| 2025-08-15 | 7.4M | -4.4% | 7.70% | 583K | 12.7 |